We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Addex Pharmaceuticals SA (ADXN) Ordinary Shares CHF1

Sell:0.19 CHF Buy:0.20 CHF Change: 0.004 CHF (2.01%)
Market closed |  Prices as at close on 7 July 2022 | Switch to live prices |
Sell:0.19 CHF
Buy:0.20 CHF
Change: 0.004 CHF (2.01%)
Market closed |  Prices as at close on 7 July 2022 | Switch to live prices |
Sell:0.19 CHF
Buy:0.20 CHF
Change: 0.004 CHF (2.01%)
Market closed |  Prices as at close on 7 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Contact details

Address:
Chemin des Mines, 9
PLAN-LES-OUATES
1202
Switzerland
Telephone:
+41 (22) 8841555
Website:
https://www.addextherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ADXN
ISIN:
CH0029850754
Market cap:
12.99 million CHF
Shares in issue:
37.89 million
Sector:
Biotechnology
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • Tim Dyer
    Chief Executive Officer, Member of the Executive Management, Member of the Board of Directors
  • Roger Mills
    Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
  • Mikhail Kalinichev
    Member of the Executive Management, Head of Translational Science
  • Robert Lutjens
    Member of the Executive Management, Head of Discovery - Biology
  • Jean-Philippe Rocher
    Member of the Executive Management, Head of Discovery - Chemistry

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.